Merck Launches Global Patient Registry Supporting Expanded Commitment to Real-World Outcomes Research in Type 2 Diabetes

On Jun 13, 2014

Whitehouse Station-based Merck, known as MSD outside the United States and Canada, announces the launch of a global registry to evaluate the experiences and outcomes of approximately 20,000 patients with type 2 diabetes in real-world settings over three years. The registry is part of Merck’s new global research initiative evaluating outcomes of patients with type 2 diabetes in everyday clinical practice. The research initiative and the new registry reflect Merck’s broader commitment to generate real-world evidence to help advance diabetes care.

The type 2 diabetes registry will be conducted at more than 900 sites across the United States, Germany, France and Japan. Led by external experts in each country, the registry will evaluate blood glucose control, healthcare resource utilization, medication adherence, quality of life and patient satisfaction.

“Type 2 diabetes is a progressive disease that affects an estimated 382 million people worldwide,” said Lawrence Blonde, M.D., chair of the Merck type 2 diabetes registry, and director of the Ochsner Diabetes Clinical Research Unit in the Department of Endocrinology, Diabetes and Metabolic Diseases at the Ochsner Medical Center in New Orleans. “By evaluating a full range of data, the Merck registry will provide valuable insights into opportunities to improve the care of people with type 2 diabetes on both regional and global levels.”

“Real-world research is a meaningful assessment of the day-to-day management of patients with diabetes—and is an important complement to clinical trials as we seek to identify unmet needs and new solutions to help improve patient outcomes, access and adherence,” Peter Stein, M.D., vice president, diabetes and endocrinology, Merck Research Laboratories. “We are thrilled to partner with our academic collaborators on this initiative, and to build on Merck’s leadership in diabetes and our commitment to scientific innovation.”

About Merck’s type 2 diabetes registry

This multinational prospective registry is designed to generate comprehensive, real-world data on patients diagnosed with type 2 diabetes. The registry will utilize various data sources, such as surveys, and administrative claims data in the United States. Through these various data sources, the registry will help to identify gaps in type 2 diabetes management and provide other important information.

Related Articles: